Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of MOTS-c and AOD-9604 — mechanism, dosing, side effects, legal status, and pricing.
MOTS-c is a mitochondrial-derived peptide encoded by the 12S rRNA gene. It is studied as a metabolic regulator that improves insulin sensitivity, promotes fat oxidation, and enhances exercise capacity, earning it the nickname 'exercise mimetic peptide.'
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. It stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full HGH.
MOTS-c
AOD-9604
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Preclinical studies in mice demonstrate improved insulin sensitivity, prevention of age-related metabolic dysfunction, and enhanced exercise capacity. Endogenous MOTS-c levels decline with age and correlate with metabolic fitness. Human trials are limited but emerging.
Phase 2 clinical trials showed modest weight loss in obese subjects over 12 weeks. Preclinical studies demonstrate significant fat reduction without affecting lean mass or glucose homeostasis. It has FDA GRAS (Generally Recognized As Safe) status for food use.
MOTS-c and AOD-9604 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs